25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

GRTX (Galera Therapeutics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Galera Therapeutics Inc together

I guess you are interested in Galera Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Galera Therapeutics Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Galera Therapeutics Inc’s Price Targets

I'm going to help you getting a better view of Galera Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Galera Therapeutics Inc

I send you an email if I find something interesting about Galera Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Galera Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Galera Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-1.47
Expected worth in 1 year
$-1.15
How sure are you?
18.5%

+ What do you gain per year?

Total Gains per Share
$0.32
Return On Investment
1,228.1%

For what price can you sell your share?

Current Price per Share
$0.03
Expected price per share
$0.021 - $0.042
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Galera Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$0.03
Intrinsic Value Per Share
$3.28 - $4.11
Total Value Per Share
$1.82 - $2.65

2.2. Growth of Galera Therapeutics Inc (5 min.)




Is Galera Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$144.3m-$126.8m-$15.4m-10.8%

How much money is Galera Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$4m-$11.4m$7.3m183.0%
Net Profit Margin0.0%-1,587.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Galera Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Galera Therapeutics Inc?

Welcome investor! Galera Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Galera Therapeutics Inc.

First you should know what it really means to hold a share of Galera Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Galera Therapeutics Inc is $0.026. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Galera Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Galera Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.47. Based on the TTM, the Book Value Change Per Share is $0.08 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.12 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Galera Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.02-62.2%-0.05-201.3%-0.15-583.0%-0.14-535.3%-0.18-708.0%-0.18-703.3%
Usd Book Value Change Per Share0.441,685.7%0.08307.0%-0.12-472.4%-0.04-170.4%-0.11-417.1%-0.05-208.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.441,685.7%0.08307.0%-0.12-472.4%-0.04-170.4%-0.11-417.1%-0.05-208.8%
Usd Price Per Share0.03-0.07-0.90-0.91-3.55-3.47-
Price to Earnings Ratio-0.46--0.38--1.04--1.16--3.63--3.57-
Price-to-Total Gains Ratio0.07--2.45--5.02--3.31--16.45--16.71-
Price to Book Ratio-0.02--0.04--0.58--0.67-2.22-2.68-
Price-to-Total Gains Ratio0.07--2.45--5.02--3.31--16.45--16.71-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.026
Number of shares38461
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.08-0.11
Usd Total Gains Per Share0.08-0.11
Gains per Quarter (38461 shares)3,070.27-4,170.46
Gains per Year (38461 shares)12,281.08-16,681.83
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1012281122710-16682-16692
2024562245520-33364-33374
3036843368330-50045-50056
4049124491140-66727-66738
5061405613950-83409-83420
6073686736760-100091-100102
7085968859570-116773-116784
8098249982380-133455-133466
901105301105190-150136-150148
1001228111228000-166818-166830

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.027.00.00.0%0.027.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%2.018.00.010.0%5.021.01.018.5%5.021.01.018.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.027.00.0%0.00.027.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%2.018.00.010.0%5.021.01.018.5%5.021.01.018.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Galera Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.4380.080+449%-0.123+128%-0.044+110%-0.108+125%-0.054+112%
Book Value Per Share---1.466-1.774+21%-1.681+15%-1.580+8%-1.038-29%-0.762-48%
Current Ratio--7.7547.280+7%4.366+78%5.203+49%5.696+36%7.026+10%
Debt To Asset Ratio--19.84415.391+29%5.401+267%7.881+152%5.219+280%4.142+379%
Debt To Equity Ratio----0%-0%-0%0.878-100%0.811-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value---142382897.100-138952519.395-2%-67569402.000-53%-60001522.465-58%177835392.121-180%243998628.474-158%
Eps---0.016-0.052+224%-0.152+838%-0.139+761%-0.184+1039%-0.183+1031%
Ev To Ebitda Ratio--18.1339.834+84%3.563+409%4.299+322%-0.441+102%-1.644+109%
Free Cash Flow Per Share---0.0230.002-1030%-0.126+455%-0.089+294%-0.138+507%-0.137+505%
Free Cash Flow To Equity Per Share---0.0160.011-243%-0.114+599%-0.049+199%-0.068+319%0.007-350%
Gross Profit Margin--1.0001.0000%1.010-1%1.0040%1.0020%1.0020%
Intrinsic Value_10Y_max--4.114----------
Intrinsic Value_10Y_min--3.284----------
Intrinsic Value_1Y_max---0.247----------
Intrinsic Value_1Y_min---0.243----------
Intrinsic Value_3Y_max---0.239----------
Intrinsic Value_3Y_min---0.238----------
Intrinsic Value_5Y_max--0.374----------
Intrinsic Value_5Y_min--0.304----------
Market Cap1962022.400-51%2955102.9005545730.605-47%67538848.000-96%68947227.535-96%268246042.121-99%262033289.867-99%
Net Profit Margin----0%-15.8720%-5.2910%-3.1740%-2.3510%
Operating Margin----0%-14.7050%-4.9020%-2.9410%-2.1780%
Operating Ratio----0%14.705-100%4.902-100%2.941-100%2.178-100%
Pb Ratio-0.018+13%-0.020-0.039+92%-0.578+2726%-0.667+3159%2.225-101%2.677-101%
Pe Ratio-0.402+13%-0.464-0.380-18%-1.038+124%-1.156+149%-3.634+683%-3.573+670%
Price Per Share0.026-15%0.0300.071-58%0.895-97%0.913-97%3.554-99%3.472-99%
Price To Free Cash Flow Ratio-0.286+13%-0.330-0.367+11%-1.636+395%-1.707+417%-4.541+1276%-4.497+1262%
Price To Total Gains Ratio0.059-15%0.068-2.450+3679%-5.015+7427%-3.306+4931%-16.452+24136%-16.715+24520%
Quick Ratio--6.8576.630+3%4.210+63%5.618+22%7.550-9%10.492-35%
Return On Assets---0.208-0.393+89%-0.316+52%-0.346+67%-0.294+41%-0.249+20%
Return On Equity----0%-0%-0%-0.2220%-0.2030%
Total Gains Per Share--0.4380.080+449%-0.123+128%-0.044+110%-0.108+125%-0.054+112%
Usd Book Value---144363000.000-142281500.000-1%-126857000.000-12%-122008000.000-15%-80038900.000-45%-58734666.667-59%
Usd Book Value Change Per Share--0.4380.080+449%-0.123+128%-0.044+110%-0.108+125%-0.054+112%
Usd Book Value Per Share---1.466-1.774+21%-1.681+15%-1.580+8%-1.038-29%-0.762-48%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value---142382897.100-138952519.395-2%-67569402.000-53%-60001522.465-58%177835392.121-180%243998628.474-158%
Usd Eps---0.016-0.052+224%-0.152+838%-0.139+761%-0.184+1039%-0.183+1031%
Usd Free Cash Flow---2238000.00053500.000-4283%-9508000.000+325%-6794750.000+204%-10437000.000+366%-10387370.370+364%
Usd Free Cash Flow Per Share---0.0230.002-1030%-0.126+455%-0.089+294%-0.138+507%-0.137+505%
Usd Free Cash Flow To Equity Per Share---0.0160.011-243%-0.114+599%-0.049+199%-0.068+319%0.007-350%
Usd Market Cap1962022.400-51%2955102.9005545730.605-47%67538848.000-96%68947227.535-96%268246042.121-99%262033289.867-99%
Usd Price Per Share0.026-15%0.0300.071-58%0.895-97%0.913-97%3.554-99%3.472-99%
Usd Profit---1592000.000-4042000.000+154%-11438250.000+618%-11007250.000+591%-14307650.000+799%-13715259.259+762%
Usd Revenue----0%22000.000-100%7333.333-100%4400.000-100%3259.259-100%
Usd Total Gains Per Share--0.4380.080+449%-0.123+128%-0.044+110%-0.108+125%-0.054+112%
 EOD+1 -7MRQTTM+16 -15YOY+21 -123Y+21 -125Y+20 -1410Y+18 -16

3.3 Fundamental Score

Let's check the fundamental score of Galera Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.402
Price to Book Ratio (EOD)Between0-1-0.018
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than16.857
Current Ratio (MRQ)Greater than17.754
Debt to Asset Ratio (MRQ)Less than119.844
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.208
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Galera Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.459
Ma 20Greater thanMa 500.027
Ma 50Greater thanMa 1000.025
Ma 100Greater thanMa 2000.030
OpenGreater thanClose0.026
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Galera Therapeutics Inc

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy that is in Phase 2a clinical trial. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Fundamental data was last updated by Penke on 2025-07-02 22:54:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Galera Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Galera Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Galera Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-1,587.2%+1,587.2%
TTM-5Y-317.4%+317.4%
5Y-317.4%10Y-235.1%-82.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--92.7%+92.7%
TTM--140.3%+140.3%
YOY-1,587.2%-196.4%-1,390.8%
3Y-529.1%-248.5%-280.6%
5Y-317.4%-343.4%+26.0%
10Y-235.1%-496.2%+261.1%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Galera Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Galera Therapeutics Inc to theΒ Biotechnology industry mean.
  • -20.8% Return on Assets means thatΒ Galera Therapeutics Inc generatedΒ $-0.21 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Galera Therapeutics Inc:

  • The MRQ is -20.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -39.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.8%TTM-39.3%+18.5%
TTM-39.3%YOY-31.6%-7.7%
TTM-39.3%5Y-29.4%-9.9%
5Y-29.4%10Y-24.9%-4.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.8%-11.6%-9.2%
TTM-39.3%-11.6%-27.7%
YOY-31.6%-11.4%-20.2%
3Y-34.6%-11.8%-22.8%
5Y-29.4%-12.0%-17.4%
10Y-24.9%-13.7%-11.2%
4.3.1.3. Return on Equity

Shows how efficient Galera Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Galera Therapeutics Inc to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means Galera Therapeutics Inc generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Galera Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-22.2%+22.2%
5Y-22.2%10Y-20.3%-1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.6%+13.6%
TTM--15.0%+15.0%
YOY--14.5%+14.5%
3Y--16.9%+16.9%
5Y-22.2%-17.5%-4.7%
10Y-20.3%-19.9%-0.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Galera Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Galera Therapeutics Inc is operatingΒ .

  • Measures how much profit Galera Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Galera Therapeutics Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Galera Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-1,470.5%+1,470.5%
TTM-5Y-294.1%+294.1%
5Y-294.1%10Y-217.8%-76.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM--249.0%+249.0%
YOY-1,470.5%-208.5%-1,262.0%
3Y-490.2%-223.8%-266.4%
5Y-294.1%-346.1%+52.0%
10Y-217.8%-475.5%+257.7%
4.3.2.2. Operating Ratio

Measures how efficient Galera Therapeutics Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Galera Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY14.705-14.705
TTM-5Y2.941-2.941
5Y2.94110Y2.178+0.762
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.110-2.110
TTM-2.684-2.684
YOY14.7053.096+11.609
3Y4.9023.652+1.250
5Y2.9414.745-1.804
10Y2.1786.614-4.436
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Galera Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Galera Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 7.75Β means the company has $7.75 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Galera Therapeutics Inc:

  • The MRQ is 7.754. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.280. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.754TTM7.280+0.474
TTM7.280YOY4.366+2.914
TTM7.2805Y5.696+1.584
5Y5.69610Y7.026-1.330
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.7543.661+4.093
TTM7.2803.846+3.434
YOY4.3664.140+0.226
3Y5.2034.688+0.515
5Y5.6965.746-0.050
10Y7.0266.147+0.879
4.4.3.2. Quick Ratio

Measures if Galera Therapeutics Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Galera Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 6.86Β means the company can pay off $6.86 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Galera Therapeutics Inc:

  • The MRQ is 6.857. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.630. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.857TTM6.630+0.227
TTM6.630YOY4.210+2.420
TTM6.6305Y7.550-0.920
5Y7.55010Y10.492-2.941
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.8572.826+4.031
TTM6.6303.182+3.448
YOY4.2103.786+0.424
3Y5.6184.311+1.307
5Y7.5505.703+1.847
10Y10.4926.454+4.038
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Galera Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Galera Therapeutics IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Galera Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 19.84Β means that Galera Therapeutics Inc assets areΒ financed with 1,984.4% credit (debt) and the remaining percentage (100% - 1,984.4%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Galera Therapeutics Inc:

  • The MRQ is 19.844. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 15.391. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ19.844TTM15.391+4.453
TTM15.391YOY5.401+9.990
TTM15.3915Y5.219+10.172
5Y5.21910Y4.142+1.077
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.8440.329+19.515
TTM15.3910.349+15.042
YOY5.4010.331+5.070
3Y7.8810.340+7.541
5Y5.2190.349+4.870
10Y4.1420.379+3.763
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Galera Therapeutics Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Galera Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Galera Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.878-0.878
5Y0.87810Y0.811+0.067
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.379-0.379
TTM-0.437-0.437
YOY-0.414-0.414
3Y-0.450-0.450
5Y0.8780.464+0.414
10Y0.8110.515+0.296
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Galera Therapeutics Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Galera Therapeutics Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -0.46 means the investor is paying $-0.46Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Galera Therapeutics Inc:

  • The EOD is -0.402. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.464. Based on the earnings, the company is expensive. -2
  • The TTM is -0.380. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.402MRQ-0.464+0.062
MRQ-0.464TTM-0.380-0.084
TTM-0.380YOY-1.038+0.659
TTM-0.3805Y-3.634+3.254
5Y-3.63410Y-3.573-0.061
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.402-2.304+1.902
MRQ-0.464-2.080+1.616
TTM-0.380-2.564+2.184
YOY-1.038-3.764+2.726
3Y-1.156-3.773+2.617
5Y-3.634-6.193+2.559
10Y-3.573-6.833+3.260
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Galera Therapeutics Inc:

  • The EOD is -0.286. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.330. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.367. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.286MRQ-0.330+0.044
MRQ-0.330TTM-0.367+0.037
TTM-0.367YOY-1.636+1.268
TTM-0.3675Y-4.541+4.174
5Y-4.54110Y-4.497-0.044
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.286-3.132+2.846
MRQ-0.330-2.705+2.375
TTM-0.367-3.666+3.299
YOY-1.636-4.405+2.769
3Y-1.707-5.059+3.352
5Y-4.541-8.477+3.936
10Y-4.497-9.304+4.807
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Galera Therapeutics Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -0.02 means the investor is paying $-0.02Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Galera Therapeutics Inc:

  • The EOD is -0.018. Based on the equity, the company is expensive. -2
  • The MRQ is -0.020. Based on the equity, the company is expensive. -2
  • The TTM is -0.039. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.018MRQ-0.020+0.003
MRQ-0.020TTM-0.039+0.019
TTM-0.039YOY-0.578+0.539
TTM-0.0395Y2.225-2.264
5Y2.22510Y2.677-0.452
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.0181.953-1.971
MRQ-0.0201.843-1.863
TTM-0.0392.112-2.151
YOY-0.5782.441-3.019
3Y-0.6672.494-3.161
5Y2.2253.661-1.436
10Y2.6774.311-1.634
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Galera Therapeutics Inc.

4.8.1. Institutions holding Galera Therapeutics Inc

Institutions are holding 9.99% of the shares of Galera Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30XTX Topco Ltd0.09580.00065211326867106.4208
2024-06-30State Street Corp000-106564-100
2024-06-30Susquehanna International Group, LLP000-286180-100
2024-06-30Atom Investors LP000-356204-100
2024-06-30Wells Fargo & Co000-1391-100
2024-06-30Jane Street Group LLC000-11410-100
2024-06-30Northern Trust Corp000-69029-100
2024-06-30Millennium Management LLC000-76630-100
2024-06-30Morgan Stanley - Brokerage Accounts000-5662-100
2024-06-30U.S. Bancorp000-3000-100
2024-06-30Good Life Advisors, LLC000-31250-100
2024-06-30GSA Capital Partners LLP000-3632627-100
2024-06-30Kestra Advisory Services, LLC000-32250-100
2024-06-30abrdn PLC000-898374-100
2024-06-30HRT FINANCIAL LLC000-15782-100
2024-06-30Parallel Advisors, LLC000-7867-100
2024-06-30Royal Bank of Canada000-35403-100
2024-06-30Summit Trail Advisors, LLC000-147658-100
2024-06-30J.W. COLE ADVISORS, INC.000-12000-100
2024-06-30Level Four Advisory Services, LLC000-26441-100
Total 0.09580.000652113-5728855-10,993.1%

4.9.2. Funds holding Galera Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30abrdn Healthcare Opportunities0.57810.001931443000
2024-10-31abrdn Healthcare Investors0.5450.001429646200
2024-09-30abrdn World Healthcare0.29730.001916170900
2024-10-31abrdn Life Sciences Investors0.23120.001312577300
Total 1.65160.006589837400.0%

5.3. Insider Transactions

Insiders are holding 32.838% of the shares of Galera Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-03-16Mark BachledaBUY110002.25
2023-03-13Chris DegnanBUY100001.96
2023-03-10Mel SorensenBUY1000001.68
2021-12-17Linda WestBUY200002.74
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Other Current Liabilities  8313261,157-539618-227391-904-513



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets7,661
Total Liabilities152,024
Total Stockholder Equity-144,363
 As reported
Total Liabilities 152,024
Total Stockholder Equity+ -144,363
Total Assets = 7,661

Assets

Total Assets7,661
Total Current Assets7,560
Long-term Assets101
Total Current Assets
Cash And Cash Equivalents 6,686
Other Current Assets 874
Total Current Assets  (as reported)7,560
Total Current Assets  (calculated)7,560
+/-0
Long-term Assets
Long-term Assets Other 101
Long-term Assets  (as reported)101
Long-term Assets  (calculated)101
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities975
Long-term Liabilities151,049
Total Stockholder Equity-144,363
Total Current Liabilities
Accounts payable 744
Other Current Liabilities -513
Total Current Liabilities  (as reported)975
Total Current Liabilities  (calculated)231
+/- 744
Long-term Liabilities
Long-term Liabilities Other 151,049
Long-term Liabilities  (as reported)151,049
Long-term Liabilities  (calculated)151,049
+/-0
Total Stockholder Equity
Common Stock75
Retained Earnings -457,955
Other Stockholders Equity 313,517
Total Stockholder Equity (as reported)-144,363
Total Stockholder Equity (calculated)-144,363
+/-0
Other
Capital Stock75
Cash and Short Term Investments 6,686
Common Stock Shares Outstanding 98,503
Liabilities and Stockholders Equity 7,661
Net Debt -6,686
Net Invested Capital -147,227
Net Working Capital 6,585



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
0
0
88,056
88,056
91,043
91,043
79,758
123,376
130,813
114,295
98,075
84,098
70,486
115,269
98,765
83,311
71,099
61,078
50,713
44,036
59,714
48,276
37,779
26,141
19,651
16,383
8,901
10,101
7,661
7,66110,1018,90116,38319,65126,14137,77948,27659,71444,03650,71361,07871,09983,31198,765115,26970,48684,09898,075114,295130,813123,37679,75891,04391,04388,05688,05600
   > Total Current Assets 
0
0
83,852
83,852
81,517
83,951
72,142
117,570
125,018
108,398
92,304
77,929
64,240
108,864
92,688
77,392
65,276
55,188
44,917
38,535
54,243
42,003
31,245
21,629
15,186
11,962
8,899
10,001
7,560
7,56010,0018,89911,96215,18621,62931,24542,00354,24338,53544,91755,18865,27677,39292,688108,86464,24077,92992,304108,398125,018117,57072,14283,95181,51783,85283,85200
       Cash And Cash Equivalents 
0
0
14,811
14,811
-81,517
16,195
15,719
18,356
21,578
15,882
15,232
15,872
13,687
38,465
17,632
19,859
19,645
17,376
12,730
4,266
25,687
24,302
24,379
18,257
13,466
10,749
8,455
8,289
6,686
6,6868,2898,45510,74913,46618,25724,37924,30225,6874,26612,73017,37619,64519,85917,63238,46513,68715,87215,23215,88221,57818,35615,71916,195-81,51714,81114,81100
       Short-term Investments 
0
0
66,706
66,706
163,034
65,082
52,226
93,934
98,939
88,527
73,919
56,904
43,833
28,062
71,073
51,358
41,302
34,631
30,039
27,331
22,064
14,453
3,985
0
0
0
0
0
0
0000003,98514,45322,06427,33130,03934,63141,30251,35871,07328,06243,83356,90473,91988,52798,93993,93452,22665,082163,03466,70666,70600
       Net Receivables 
0
0
914
870
0
0
0
0
0
0
0
0
0
37,500
0
0
0
0
0
3,242
0
0
0
0
0
0
0
635
0
063500000003,2420000037,50000000000087091400
       Other Current Assets 
0
0
0
1,465
0
2,674
4,197
5,280
4,501
7,978
6,306
10,306
13,440
4,837
7,966
12,350
8,658
6,362
4,246
6,938
6,492
3,248
2,881
3,372
3,060
1,213
444
1,077
874
8741,0774441,2133,0603,3722,8813,2486,4926,9384,2466,3628,65812,3507,9664,83713,44010,3066,3067,9784,5015,2804,1972,67401,465000
   > Long-term Assets 
0
0
0
4,204
-81,517
7,092
7,616
5,806
5,795
5,897
5,771
6,169
6,246
6,405
6,077
5,919
5,823
5,890
5,796
5,501
5,471
6,273
6,534
4,512
4,465
4,421
2
100
101
10110024,4214,4654,5126,5346,2735,4715,5015,7965,8905,8235,9196,0776,4056,2466,1695,7715,8975,7955,8067,6167,092-81,5174,204000
       Property Plant Equipment 
0
0
568
568
1,890
1,890
1,846
1,749
1,637
1,840
1,676
1,553
1,630
1,470
1,312
823
738
654
570
481
418
1,496
1,447
1,283
1,236
1,192
0
0
0
0001,1921,2361,2831,4471,4964184815706547388231,3121,4701,6301,5531,6761,8401,6371,7491,8461,8901,89056856800
       Goodwill 
0
0
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881
0
0
0
00088188188188188188188188188188188188188188188188188188188188188188188188100
       Intangible Assets 
0
0
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
0
0
0
0002,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,25800
       Other Assets 
0
0
497
497
2,063
2,063
2,631
918
1,019
918
956
2,007
1,477
1,796
1,626
1,957
1,946
2,097
2,087
0
0
1,638
0
0
0
0
0
0
0
00000001,638002,0872,0971,9461,9571,6261,7961,4772,0079569181,0199182,6312,0632,06349749700
> Total Liabilities 
0
0
26,974
192,876
50,726
50,726
224,378
53,768
77,755
74,058
73,380
77,980
81,059
140,786
141,932
141,315
141,570
144,324
148,215
153,217
157,327
163,275
164,332
157,326
154,342
154,415
151,963
153,770
152,024
152,024153,770151,963154,415154,342157,326164,332163,275157,327153,217148,215144,324141,570141,315141,932140,78681,05977,98073,38074,05877,75553,768224,37850,72650,726192,87626,97400
   > Total Current Liabilities 
0
0
6,444
6,444
8,355
8,355
9,083
9,694
12,648
12,402
10,503
13,968
15,855
16,843
15,724
12,935
10,931
10,986
11,632
13,379
13,266
13,622
12,630
4,957
2,013
2,126
914
1,666
975
9751,6669142,1262,0134,95712,63013,62213,26613,37911,63210,98610,93112,93515,72416,84315,85513,96810,50312,40212,6489,6949,0838,3558,3556,4446,44400
       Short-term Debt 
0
0
0
0
0
286
291
297
285
268
250
238
592
568
542
516
468
344
218
88
0
256
131
266
136
157
0
0
0
00015713626613125608821834446851654256859223825026828529729128600000
       Accounts payable 
0
0
3,867
3,867
5,470
5,470
5,218
3,945
6,640
6,767
4,013
5,146
9,217
8,272
7,181
5,044
4,131
3,588
3,591
3,581
5,937
5,516
3,715
1,375
1,046
812
296
1,275
744
7441,2752968121,0461,3753,7155,5165,9373,5813,5913,5884,1315,0447,1818,2729,2175,1464,0136,7676,6403,9455,2185,4705,4703,8673,86700
       Other Current Liabilities 
0
0
0
2,577
0
2,599
3,574
5,452
5,723
5,367
6,240
8,584
6,046
8,003
8,001
7,375
6,332
7,054
7,823
9,710
7,329
7,850
8,784
3,316
831
1,157
618
391
-513
-5133916181,1578313,3168,7847,8507,3299,7107,8237,0546,3327,3758,0018,0036,0468,5846,2405,3675,7235,4523,5742,59902,577000
   > Long-term Liabilities 
0
0
0
186,432
0
42,371
215,295
44,074
65,107
61,656
62,877
64,012
65,204
123,943
126,208
128,380
130,639
133,338
136,583
139,838
144,061
149,653
151,702
152,369
152,329
152,289
151,049
152,104
151,049
151,049152,104151,049152,289152,329152,369151,702149,653144,061139,838136,583133,338130,639128,380126,208123,94365,20464,01262,87761,65665,10744,074215,29542,3710186,432000
       Long term Debt Total 
0
0
0
20,220
0
41,395
42,313
43,251
64,346
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000064,34643,25142,31341,395020,220000
       Other Liabilities 
0
0
20,530
20,530
41,693
41,693
42,611
43,540
64,635
61,242
62,521
63,716
64,969
123,771
126,098
128,336
130,639
133,338
136,583
203
203
203
0
0
0
0
0
0
0
0000000203203203136,583133,338130,639128,336126,098123,77164,96963,71662,52161,24264,63543,54042,61141,69341,69320,53020,53000
       Deferred Long Term Liability 
0
0
0
0
1,747
1,747
2,103
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000002,1031,7471,7470000
> Total Stockholder Equity
0
0
-104,820
-104,820
61,082
40,317
-144,620
69,608
53,058
40,237
24,695
6,118
-10,573
-25,517
-43,167
-58,004
-70,471
-83,246
-97,502
-109,181
-97,613
-114,999
-126,553
-131,185
-134,691
-138,032
-143,062
-143,669
-144,363
-144,363-143,669-143,062-138,032-134,691-131,185-126,553-114,999-97,613-109,181-97,502-83,246-70,471-58,004-43,167-25,517-10,5736,11824,69540,23753,05869,608-144,62040,31761,082-104,820-104,82000
   Common Stock
0
0
2
2
2
19
-344,160
25
25
25
25
25
25
26
26
26
27
27
27
28
43
44
54
54
54
54
54
75
75
75755454545454444328272727262626252525252525-344,1601922200
   Retained Earnings Total Equity00000000-396,034-378,32400000-276,669-254,283-235,56800000000000
   Accumulated Other Comprehensive Income 
0
0
0
3
-104,820
81
55
38
686
316
123
12
10
3
-2
-14
-61
-110
-93
-22
16
5
0
0
0
0
0
0
0
0000000516-22-93-110-61-14-231012123316686385581-104,8203000
   Capital Surplus 
0
0
0
0
0
0
0
230,895
232,114
0
0
241,649
243,675
251,123
0
0
0
0
0
269,137
298,362
0
0
0
0
0
0
0
0
00000000298,362269,13700000251,123243,675241,64900232,114230,8950000000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 
0
0
3
-165,902
81
169,954
172,080
230,895
232,114
238,320
240,049
241,649
243,675
251,123
256,104
258,086
261,108
262,940
264,700
269,137
298,362
301,698
305,212
306,167
307,042
307,765
308,316
308,247
313,517
313,517308,247308,316307,765307,042306,167305,212301,698298,362269,137264,700262,940261,108258,086256,104251,123243,675241,649240,049238,320232,114230,895172,080169,95481-165,902300



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-3,843
Gross Profit-3,843-3,843
 
Operating Income (+$)
Gross Profit-3,843
Operating Expense-14,153
Operating Income-20,160-17,996
 
Operating Expense (+$)
Research Development3,151
Selling General Administrative11,002
Selling And Marketing Expenses0
Operating Expense14,15314,153
 
Net Interest Income (+$)
Interest Income554
Interest Expense-0
Other Finance Cost-0
Net Interest Income554
 
Pretax Income (+$)
Operating Income-20,160
Net Interest Income554
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-19,160-21,160
EBIT - interestExpense = 0
-19,160
-18,957
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-19,160
Earnings Before Interest and Taxes (EBITDA)-20,160
 
After tax Income (+$)
Income Before Tax-19,160
Tax Provision--203
Net Income From Continuing Ops-18,957-18,957
Net Income-18,957
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses17,996
Total Other Income/Expenses Net1,000-554
 

Technical Analysis of Galera Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Galera Therapeutics Inc. The general trend of Galera Therapeutics Inc is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Galera Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Galera Therapeutics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Galera Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.037 < 0.0375 < 0.042.

The bearish price targets are: 0.0231 > 0.021 > 0.021.

Know someone who trades $GRTX? Share this with them.πŸ‘‡

Galera Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Galera Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Galera Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Galera Therapeutics Inc. The current macd is 0.00046952.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Galera Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Galera Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Galera Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Galera Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartGalera Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Galera Therapeutics Inc. The current adx is 59.64.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Galera Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Galera Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Galera Therapeutics Inc. The current sar is 0.03412352.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Galera Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Galera Therapeutics Inc. The current rsi is 47.46. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Galera Therapeutics Inc Daily Relative Strength Index (RSI) ChartGalera Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Galera Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Galera Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Galera Therapeutics Inc Daily Stochastic Oscillator ChartGalera Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Galera Therapeutics Inc. The current cci is -26.09262883.

Galera Therapeutics Inc Daily Commodity Channel Index (CCI) ChartGalera Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Galera Therapeutics Inc. The current cmo is -10.39551223.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Galera Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartGalera Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Galera Therapeutics Inc. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Galera Therapeutics Inc Daily Williams %R ChartGalera Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Galera Therapeutics Inc.

Galera Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Galera Therapeutics Inc. The current atr is 0.00290136.

Galera Therapeutics Inc Daily Average True Range (ATR) ChartGalera Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Galera Therapeutics Inc. The current obv is 33,592,978.

Galera Therapeutics Inc Daily On-Balance Volume (OBV) ChartGalera Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Galera Therapeutics Inc. The current mfi is 19.05.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Galera Therapeutics Inc Daily Money Flow Index (MFI) ChartGalera Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Galera Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-02-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-24MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-03STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-23MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-30BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-09MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-02BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Galera Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Galera Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.459
Ma 20Greater thanMa 500.027
Ma 50Greater thanMa 1000.025
Ma 100Greater thanMa 2000.030
OpenGreater thanClose0.026
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Galera Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Galera Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Galera Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Galera Therapeutics Inc

I send you an email if I find something interesting about Galera Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Galera Therapeutics Inc.

Receive notifications about Galera Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.